GVHD research hub

Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor

This study compares two medicines, Grafalon and Thymoglobulin, used to prevent a common complication called GVHD after a stem cell transplant for blood cancers. It focuses on older patients (age 50-70) with AML or MDS, finding the safest and most effective treatment.